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INTRODUCTION 72 
Hyponatremia (hypoNa, serum sodium levels <135 mEq/L), is the most frequently observed electrolyte disorder in 73 
clinical practice, affecting up to 15-30% of hospitalized patients (1). HypoNa is characterized by an excess of water 74 
relative to exchangeable total body sodium, that can be normal, increased or decreased. As a consequence, hypoNa can 75 
be classified by the fluid volume status of the patient (euvolemic, hypovolemic and hypervolemic hypoNa), or by plasma 76 
tonicity, i.e., the effective osmolality, (isotonic, hypertonic and hypotonic hypoNa). Hypotonic hypoNa is the most 77 
commonly observed form in daily clinical practice (2). Severe hypoNa, especially if acutely developed (i.e in less than 78 
48 hours), may determine major neurological symptoms due to brain edema, a potentially life-threatening complication 79 
if not promptly recognized and treated (3). However, even mild hypoNa  (130-134 mEq/L) may also be associated with 80 
other strictly related clinical problems, often insidious and scarcely symptomatic, such as bone demineralization or gait 81 
instability and attention deficits, which may increase the risk of falls and bone fractures, especially in the elderly (4-8). 82 
Accordingly, recent meta-analyses have shown that even milder forms of hypoNa are associated with an increased risk 83 
of mortality in different clinical settings (9), along with prolonged hospital stay, increased readmission rates and higher 84 
hospital costs (10). 85 
Although the main  mechanisms of renal sodium and water handling, especially for what concerns the fine regulation by 86 
the distal  nephron, have been fully elucidated (11), several clinical issues make the approach to hypoNa a complex task. 87 
In fact, on one hand it should be timely diagnosed and appropriately managed according to the severity of the neurological 88 
status, but on the other hand an overly rapid correction may cause neurological damage possibly leading to the Osmotic 89 
Demyelination Syndrome (ODS) (12-14). Conditions that may be associated with a risk of hypercorrection of hypoNa 90 
and their related mechanisms are showed in Table 1. 91 
Nevertheless,  despite its high prevalence, especially among hospitalized patients, and its clinical impact, hypoNa is often 92 
neglected, or under- or mistreated (15). This is mainly due to both an empirical approach (i.e. not pathophysiology-driven) 93 
and to the high degree of heterogeneity of the clinical settings where hypoNa is encountered.  94 
In recent years a new class of drugs, namely the vasopressin receptor antagonists or vaptans, has become available for the 95 
treatment of hypoNa secondary to the Syndrome of Inappropriate Antidiuresis (SIAD), one of the most frequent causes 96 
of hypoNa (16). Tolvaptan is the only licensed vaptan in Europe, so far (12). However, there is no  agreement between 97 
the European Guidelines (17) and the recommendations of an US Expert Group (14) concerning the use of vaptans in 98 
clinical practice (18). 99 
On this basis, a task force generated by the Fluid and Electrolytes Disorder Club of the Italian Society of Endocrinology, 100 
the Italian Society of Nephrology and the Italian Association of Medical Oncology has joined together, in order to prepare 101 
a practical guide to recognize and manage hypoNa in different clinical settings.  102 
In the intention of the task-force the present paper should be considered nor as a formal Guideline nor as an all-inclusive 103 
in-depth review on the topic. Rather, this paper should be viewed as a pocket guide to support the practical approach to 104 
hyponatremic patients by different specialists. 105 
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We propose a simplified diagnostic algorithm for hypoNa (Figure 1, Table 2) and a treatment algorithm  for hypoNa 106 
secondary to SIAD (Figure 2). The treatment strategies for hypovolemic (rehydration) or hypervolemic hypoNa (fluid 107 
restriction, hypertonic saline solution, furosemide) are very well established and  for a detailed description we redirect 108 
the reader to the already mentioned recommendations/guidelines (14, 17). Here, we would like to remind that fluid 109 
restriction is not very effective and in several clinical situations this approach aiming to correct hypoNa is going to fail 110 
(19). 111 
 112 
HYPONATREMIA IN ONCOLOGY 113 
Prevalence and etiology: 114 
HypoNa in patients with cancer is a common finding because three major pathogenetic factors may concur to its 115 
development: the tumor, through the ectopic secretion of the antidiuretic hormone (ADH), also named vasopressin, the 116 
anti-neoplastic treatments, and again the tumor itself, through non-hormonal mechanisms.  117 
About 14% of all cases of hypoNa occurs in oncological patients (3). SIAD is one of the leading causes of hypoNa in 118 
inpatients with cancer, affecting 1 to 2% of the entire cancer population (20, 21). The likelihood that SIAD is the cause 119 
of hypoNa in cancer patients is >30% (22). 120 
SIAD is commonly reported in small-cell lung cancer. However, hypoNa has been also reported in other tumors, such as 121 
gastrointestinal, genitourinary, breast, prostate or hematological malignancies. SIAD in these patients may also be caused 122 
by pharmacological treatments, e.g. by a number of chemotherapeutic agents, opioid analgesics, antidepressants, 123 
including tricyclics and selective serotonin reuptake inhibitors (SSRI), as well as phenothiazines used as antiemetic agents 124 
(Table 3)  (23). Of notice, hypoNa in oncology patients may be secondary to other conditions besides SIAD (Table 4) 125 
(22), and for this reason a careful differential diagnosis is needed. Finally, hypoNa can be precipitated by fluid and salt 126 
losses due to emesis or diarrhea, with severely symptomatic acute hypoNa that can be superimposed to a relatively stable 127 
chronic electrolyte imbalance. 128 
Mortality: 129 
HypoNa significantly contributes to both morbidity and mortality in cancer patients, and it is an independent prognostic 130 
marker: in a large study, the hazard ratio risk of 90-day mortality for mild, moderate, and severe hypoNa was 2.04, 4.74 131 
and 3.46, respectively (24).  132 
Notes on treatment: 133 
In general, the treatment strategy of hypoNa in oncologic patients is not different  from that suggested by the available 134 
recommendations (12-14). 135 
However, specific situations may occur. For instance, in patients with mild hypoNa secondary to SIAD, fluid restriction 136 
may be problematic, because of the need of parenteral hydration used during chemotherapy.  137 
The use of urea for the treatment of hypoNa, especially in cases of SIAD, has also been proposed since the ‘80s (25, 26). 138 
The rationale of this approach is based on the capability of urea to increase the free water clearance by the kidney. The 139 
urea dosages usually used in patients with SIAD  to correct serum sodium range between 15–30 g/day taken orally after 140 
a meal in one or two doses (25).  141 
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While a few non controlled studies (27) (28) have reported that urea is effective in normalizing hypoNa, hypercorrection 142 
with hypernatremia has also been reported in the same studies. In fact, the urea-induced increase in serum sodium 143 
concentration is not easily predicted, as it depends on both hydration status and urine osmolality. Thus, while the European 144 
Guidelines (13) recommend urea as the treatment of choice in patients with SIAD when water restriction is ineffective or 145 
not feasible, poor palatability, scarce clinical experience  and the risk of hypercorrection suggest that advantages and 146 
disadvantages of urea should be balanced against the possible use of vasopressin receptor antagonists in this clinical 147 
setting.  148 
Therefore, a valuable option in cancer patients with SIAD could be represented by vaptans. In a recent prospective study 149 
on small cell lung cancer patients with severe SIAD, tolvaptan led to an effective correction and stabilization of the serum 150 
sodium levels, also enabling patients to receive chemotherapy without any delay (29). In addition, the use of vaptans may 151 
avoid withdrawal of hypoNa-inducing chemotherapies.  152 
The duration of treatment for hypoNa is largely dependent on the cause. In drug-induced hypoNa, the electrolyte 153 
alteration is usually reverted within days after the cessation of the involved drug. Conversely, in ADH secreting tumors, 154 
hypoNa usually requires a longer and somewhat unpredictable duration of therapy, which is also dependent on the 155 
response to anti-tumoral  treatments (30). 156 
In summary, we suggest that hypoNa should be carefully taken into account and timely corrected in oncology patients, 157 
preferably avoiding severe fluid restriction or agents that may increases nausea (urea), taking into account that the 158 
normalization of sodium levels has been found to have a positive effect on the prognosis and length of in-hospital stay 159 
(31). 160 
 161 
HYPONATREMIA IN THE ELDERLY 162 
Prevalence and etiology: 163 
The prevalence of hypoNa is increased in elderly patients compared with that in the general population, reaching almost 164 
50% of all acute geriatric admissions (32, 33).  165 
In the elderly, the etiology of hypoNa is multifactorial in 50–75% of cases (34, 35). SIAD is the most common cause, 166 
even if a risk of over-diagnosis has been claimed (34). Other frequent causes are congestive heart failure, water and 167 
sodium homeostasis alterations, renal and hepatic dysfunction, and especially drug-induced hypoNa, because older people 168 
often receive multiple pharmacological treatments (Table 5) (35) . 169 
In elderly patients alterations of electrolyte and water balance are favoured by age-related reduction in total body water, 170 
reduced renal function (36), decreased cortical blood flow and glomerular filtration rate, impaired responsiveness to 171 
sodium balance changes (37), osmoreceptors hypersensitivity, and higher ADH release (38). Additionally, the ability to 172 
excrete free water is reduced (39).  173 
Mortality: 174 
HypoNa is associated with increased all-cause mortality in elderly subjects: a recent study showed that the adjusted 175 
hazards ratio (95%CI) in hyponatremic men without chronic kidney disease (CKD), stroke or heart failure was 1.30 176 
(confidence interval 1.02 to 1.66) (40). 177 
Notes on clinical features and diagnosis: 178 
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HypoNa in the elderly is mostly mild, chronic and apparently asymptomatic, but it often associated with bone 179 
demineralization and cognitive impairment, increased risk of falls and fractures (7, 34). 180 
Conversely, acute hypoNa in the elderly is characterized by confusion, irritability, lethargy, anorexia and nausea, but pre-181 
existing cognitive and sensory impairment might interfere with timely identification of symptoms  (34, 38).  182 
The diagnosis in older people may be challenging, due to polypharmacy, difficult assessment of fluid volume status by 183 
clinical examination, presence of several confounding co-morbidities, and difficulties in obtaining a reliable clinical 184 
history (34, 41). 185 
Notes on treatment: 186 
Treatment of both acute and chronic hypoNa in the elderly does not differ from that of younger patients (14, 34). Vaptans 187 
could represent an option in hypoNa secondary to SIAD also in the elderly. The use of low doses - at least initially - may 188 
reduce the risk of overtreatment. Appropriate hydration should be strictly monitored. In the case of hypovolemic hypoNa, 189 
rehydration should be provided with special caution, especially when cardiac function is reduced and/or chronic kidney 190 
disease coexist (36).  191 
 192 
HYPONATREMIA IN CONGESTIVE HEART FAILURE    193 
Prevalence and etiology 194 
The prevalence of hypoNa among patients with heart failure (HF) is about 20-25% (42) (43) (44) (45) (46), however, it 195 
may be higher in patients admitted for acutely decompensated HF (ADHF): 38% at hospital admission and 28% as new-196 
onset hyponatremia during hospital stay (47).  197 
In this clinical setting, effective arterial blood volume (EABV) is decreased, due to low cardiac output and systemic 198 
venous congestion. The decreased EABV releases the tonic baroreceptor-dependent inhibition on efferent sympathetic 199 
tone and vasopressin release. The ensuing hyperactivation of the sympathetic nervous system, together with renal 200 
hypoperfusion, is associated with decreased glomerular filtration rate, increased proximal sodium reabsorption and 201 
reduced sodium delivery to distal nephron segments. These latter mechanisms and the high circulating vasopressin levels 202 
– always disproportionate to the reduced plasma tonicity - are mainly responsible for decreased free water clearance and 203 
development of HypoNa. On the other hand, secondary hyperaldosteronism due to increased renin release and elevated 204 
circulating angiotensin II favors increased sodium reabsorption at the distal nephron, increased total body sodium balance, 205 
edema formation and hypervolemic hypoNa (48). 206 
Mortality 207 
A correlation between hypoNa and overall mortality was first documented 30 years ago in HF. Moreover, in patients with 208 
ADHF hypoNa is associated with an increased mortality and risk of re-hospitalization (47) (49). In particular, a recent 209 
meta-analysis of the available data documented that hypoNa doubled the risk of mortality in patients with HF (9). In 210 
addition,  patients admitted for ADHF and normal serum sodium values at admission, it has also been shown that the 211 
development and worsening of hypoNa during hospital stay are strongly correlated with an increase in overall and 212 
cardiovascular mortality (50). 213 
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Finally, a recent retrospective study in patients admitted for ADHF with hypoNa at admission reported that even persistent 214 
hypoNa at the time of hospital discharge is associated with a significant increase re-hospitalization or mortality at 30 days 215 
(51).  216 
Notes on treatment 217 
Clearly, sodium and fluid restriction, diuretics, blockers of the renin-angiotensin-aldosterone system, and betablockers, 218 
are the mainstay of treatment in patients with HF. While hypoNa bears a clear negative prognostic impact, few data are 219 
currently available in the literature to clearly ascertain whether correction of hypoNa per se may ameliorate outcomes in 220 
patients with HF (13). As a matter of fact, long-term treatment with tolvaptan in patients with HF was not associated with 221 
decreased mortality or risk of re-hospitalization compared with placebo, notwithstanding greater weight loss, better 222 
dyspnea relief, and a significant increase in serum sodium values at discharge (52). However, a post-hoc analysis of the 223 
Acute and Chronic Therapeutic Impact of a Vasopressin antagonist (ACTIV) study (53) suggested a possible correlation 224 
between increased serum sodium levels and increased survival. Furthermore, a post-hoc analysis of the Efficacy of 225 
Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial showed decreased incidence 226 
of the combined endpoint of cardiovascular mortality and cardiovascular morbidity in tolvaptan-treated patients with 227 
serum sodium values Na <130 mEq/L (54). Thus, expert consensus by US investigators (14) suggested that vaptans 228 
(tolvaptan, and possibly conivaptan, not licensed in Europe, so far) may represent a useful therapeutic tool in patients 229 
with CHF and mild-to-moderate hyponatremia. On the other hand, based on the results of an extended meta-analysis 230 
indicating a non-significant trend towards increased mortality in hyponatremic patients with expanded extracellular fluid 231 
volume, European guidelines (13) are against the use of vaptans in conditions where hyponatremia is associated with 232 
expanded extracellular fluid volume. A faster decongestion with dyspnea relief represents a desirable goal in the treatment 233 
of patients with ADHF, and no cases of osmotic myelinolisis have been reported either in the ACTIV and EVEREST 234 
trials or in the subgroup of patients with CHF enrolled in the Study of Ascending Levels of Tolvaptan in Hyponatremia 235 
1 and 2 (SALT-1 and SALT-2) trials (55). For these reasons, the use of tolvaptan may be envisaged as a potentially useful 236 
add-on treatment strategy in patients with CHF and mild-to moderate hypoNa. However, very recently, the Targeting 237 
Acute Congestion with Tolvaptan in Congestive Heart Failure (TACTICS-HF) trial (56) reported no significant 238 
differences in dyspnea relief and in-hospital or post-discharge clinical outcomes in patients with ADHF treated with 239 
tolvaptan 30 mg given at 0, 24 and 48 hours on top of fixed-dose furosemide compared with patients receiving placebo, 240 
despite greater weight loss and net fluid loss in tolvaptan-treated patients. Thus, at the present time no firm 241 
recommendation about the use of vaptans in CHF can be supported by the available literature data.  242 
 243 
HYPONATREMIA IN DECOMPENSATED LIVER CIRRHOSIS 244 
Prevalence and etiology 245 
The prevalence of hypoNa in patients admitted for decompensated liver cirrhosis reaches 57% (57). Between 21% and 246 
28% of patients have serum sodium values <130 mEq/L (57-59), whereas severe hypoNa (serum Na <120 mEq/L) is 247 
relatively infrequent (<1.2%) in this setting (57). 248 
Post-sinusoidal capillary hypertension, hypoalbuminemia and splanchnic vasodilation play a pivotal role in ascites 249 
accumulation; specifically, overproduction of nitric oxide, mainly due to circulating endotoxin associated with bacterial 250 
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translocation, maintains splanchnic vasodilation (60). In this clinical setting, pathophysiological mechanisms triggered 251 
by decreased EABV are essentially the same as in HF. Thus, while total body sodium balance is increased, the 252 
development of hypoNa is facilitated by reduced sodium delivery to the distal nephron and high circulating vasopressin 253 
levels  (60). 254 
Mortality 255 
The negative prognostic role of hypoNa in patients with liver cirrhosis has been clearly documented (59, 60). In a study 256 
performed in 6769 patients with liver failure waiting for liver transplantation, of whom 422 had deceased within 90 days 257 
since entering the waiting list, the investigators found an increased risk of death associated with hypoNa, even independent 258 
of the MELD score (61). Accordingly a recent meta-analysis of the available data documented that hypoNa was associated 259 
with more than 3-fold increased risk of mortality in patients with cirrhosis  (9). 260 
Notes on treatment 261 
In patients with liver failure, treatment with vaptans has been shown to ameliorate fluid balance in some studies (62-64). 262 
Moreover, treatment with satavaptan was associated with greater increase in serum sodium values and decreased ascites 263 
formation in cirrhotic patients receiving either diuretics (65) and spironolactone (59). However, one of those studies (65) 264 
also found an increase in the risk of death due to complication of cirrhosis in patients treated with both satavaptan and 265 
diuretics, which subsequently lead to drug withdrawal from commerce. Lixivaptan, on top of standard treatment with 266 
spironolactone, proved to be effective in increasing free water clearance and serum sodium values in patients with 267 
decompensated liver cirrhosis (66). 268 
Tolvaptan, so far the only vaptan approved in Europe, so far, and allowed only in patient with hypoNa secondary to SIAD, 269 
has been also tested on top of standard treatment with furosemide and spironolactone in patients with decompensated 270 
liver cirrhosis. Although the drug proved to be effective, also at low doses (e.g., 3.5 and 7.5 mg/day), in reducing ascites 271 
volume and body weight (67), as well as in increasing serum sodium values (68, 69), however both the European 272 
guidelines (13) and the US expert consensus document (14) recommend against the use of vaptans in patients with liver 273 
disease. Anyway, as hypoNa may complicate the use of high-dose loop diuretics in oliguric patients with refractory ascites 274 
and may predispose them to hepatic encephalopathy, a cautious use of tolvaptan in combination with diuretics may 275 
represent a treatment strategy that should be explored in future research (60). In any case, liver function should be closely 276 
monitored, and the drug should be discontinued if worsening of it is detected.  277 
 278 
HYPONATREMIA IN CHRONIC KIDNEY DISEASE 279 
Prevalence and etiology 280 
Prevalence and incidence values of hypoNa in chronic kidney disease (CKD) are respectively 13.5% and 26% (mean 281 
follow-up 5.5 years) (70). HypoNa is especially common among patients with stage 5 CKD on dialysis (End-Stage Renal 282 
Disease, ESRD): 29.3% prevalence in hemodialysis, 14.5% incidence in peritoneal dialysis (71).  283 
Three main pathogenetic mechanisms may lead to hypoNa in renal patients (72): 284 
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 Direct renal sodium loss, such as in salt-losing nephropathies (chronic pyelonephritis, chronic drug-associated 285 
or toxic tubule-interstitial), characterized by reduced renal sodium reabsorption, sodium and potassium 286 
depletion, reduced concentration ability, hypovolemia and ADH stimulation (73). The consequence is hypoNa 287 
with volume depletion. 288 
 Reduced urinary dilution capacity due to severe impairment of glomerular filtration rate with ensuing lower 289 
availability of preurine at the diluting segments of the distal nephron and reduced ability to generate free water. 290 
In this case hypoNa will be euvolemic or hypervolemic (74) (72). 291 
 Oligoanuria or anuria along with free water/hypotonic fluid intakes exceeding losses, such as  the case of ESRD 292 
on chronic dialysis or in acute kidney injury. These forms of hypoNa are usually hypervolemic (74). 293 
Mortality 294 
Low sodium levels are associated with increased mortality risk, both in CKD patients on conservative treatment (70) and 295 
in ESRD patients on dialysis (75) (76, 77). 296 
Notes on treatment 297 
There is paucity of data in the literature concerning the treatment of hypoNa in patients with CKD on conservative therapy. 298 
The oral vasopressin V2-receptor antagonist tolvaptan has been tested in small studies performed in CKD patients with or 299 
without congestive heart failure (78). On the whole, a significant increase in urine volume was observed, together with 300 
an increase in serum sodium concentration. Moreover, treatment with tolvaptan was not associated with deterioration of 301 
kidney function in these patients. 302 
The problems of the treatment of hypoNa during renal replacement therapy (RRT), and the inherent risks of overcorrection 303 
and osmotic demyelization syndrome, have been addressed mainly in the critically ill patients. Specifically, reducing 304 
serum sodium concentration in the substitution fluids has been advocated as the best approach to avoid the risk of 305 
overcorrection during continuous veno-venous hemofiltration or continuous veno-venous hemodialysis (79). When 306 
standard intermittent hemodialysis is chosen, sodium concentration in the dialysate should be reduced to a minimum of 307 
130 mEq/L, and blood flow rate as low as 50 mL/min together with short duration (e.g., 3 hours) of dialysis session should 308 
be prescribed (80). 309 
 310 
HYPONATREMIA IN NEUROLOGY 311 
Prevalence and etiology: 312 
HypoNa is a frequent complication of traumatic brain injury and meningitis (81).  313 
Limited information is available for other neurological disorders. A large Swedish registry study documented that epilepsy 314 
and stroke accounted for about 10% of all cases of hypoNa (82).  315 
In subjects with stroke, many factors including dietary sodium restriction for hypertension control, use of thiazide 316 
diuretics and infections might precipitate hypoNa (83).  317 
10 
 
 10 
Several antiepileptic drugs (AEDs) and in particular carbamazepine, oxcarbazepine, eslicarbazepine and levetiracetam 318 
may cause asymptomatic or mildly symptomatic hypoNa secondary to SIAD, which in turn may exacerbate seizures 319 
(Table 3) (81). 320 
HypoNa can occur in Guillain–Barré syndrome (GBS) as a consequence of SIAD caused by the intravenous 321 
immunoglobulin therapy, or of renal salt wasting syndrome as part of GBS-related dysautonomia (84). 322 
Mortality: 323 
HypoNa is associated with an increased risk of mortality in patients with neurological diseases: in a Danish cohort study, 324 
the adjusted 30-day relative risk of death among hyponatremic patients compared to patients with normonatremia was 1.5 325 
(0.9 –2.5) (85). 326 
Serum sodium evaluation should be mandatory in the presence of neurological symptoms. Routine sodium monitoring 327 
for patients receiving AEDs is not usually necessary, except in elderly subjects or in those receiving AED polytherapy or 328 
sodium depleting drugs (81). 329 
Notes on treatment: 330 
HypoNa in neurological patients should be managed according to the general recommendations. Treatment mainly 331 
depends on etiology; it has been shown for instance that in traumatic brain injury treatment usually lasts 0.5-2 years (30). 332 
In SIAD caused by AEDs, the possibility to reduce the dose, switch to a different drug or stop treatment should be 333 
evaluated together with the neurologist. 334 
  335 
HYPONATREMIA IN NEUROSURGERY  336 
Prevalence and etiology: 337 
Hypotonic hypoNa is a frequent finding in the neurosurgical patients, with the highest rate (20-50%) in some series among 338 
patients with subarachnoid hemorrhage (SAH) (86, 87). Observational studies have shown that brain tumors, during their 339 
course, may be associated with hypoNa in about 15-20% of cases (86). The occurrence of hypoNa as a result of 340 
transphenoidal surgery varies a lot in the different series, depending on the selection criteria. Symptomatic hypoNa was 341 
much less frequent (4-7%) than asymptomatic hypoNa, which in some series occurred in up to 20-35% of patients, 342 
according to serum sodium measured every day for at least 12 days after surgery (88-90). 343 
Some neurosurgical disorders, such as acute and chronic SAH, subdural hematoma, hemorrhagic stroke, tumors, cysts, 344 
metastases, and inflammatory diseases of the brain, pituitary, or hypothalamus, become harder to manage when hypoNa 345 
develops (86, 87, 90-92). Such a complication may occur both before and after surgery. HypoNa may also be observed at 346 
presentation in patients with pituitary apoplexy yet much less frequently than hypernatremia due to diabetes insipidus 347 
(DI).  348 
Mortality 349 
Besides hypoNa, several other factors may contribute to increase the mortality risk in the neurosurgery setting. A recent 350 
systematic review, aimed at characterizing the effect of hypoNa on morbidity and mortality after SAH, included thirteen 351 
studies with a total number of 2387 patients and showed that hypoNa was associated with increased morbidity (especially 352 
due to vasospasm), but it did not influence mortality (87). Interestingly, a recent retrospective observational study 353 
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reviewed 198 consecutive patients with SAH and indicated sodium fluctuation, rather than hypoNa per se, as a significant 354 
factor associated with worse neurologic outcome (91) 355 
Specific notes on clinical features and diagnosis: 356 
Most observational studies have shown that SIAD is the commonest cause of hypotonic hypoNa in neurosurgical patients 357 
(86). However, in this setting it is essential to differentiate SIAD and cerebral salt wasting syndrome (CSWS) as a possible 358 
cause of hypoNa, especially in pediatric series and in patients with SAH (86, 92, 93). The differential diagnosis between 359 
CSWS and SIAD may not be easy in clinical practice, the former having hypovolemia as a crucial point for the proper 360 
diagnosis  (94). 361 
In the evaluation of the hyponatremic patient after neurosurgery, it is essential to consider the possible occurrence of DI 362 
with a triphasic pattern (95) and the possible late occurrence of hypoNA due to SIAD, which can occur after the patient 363 
has been discharged (88-90)  364 
In order to improve the outcome in neurosurgical patients, we suggest careful monitoring of  serum sodium on admission 365 
and during the hospital stay. Whenever hypoNa is observed, a proper work-up has to be instructed to elucidate the 366 
underlying cause, bearing in mind that the evaluation of extracellular fluid volume status is mandatory. Also in case of 367 
early discharge the patients should receive clear instructions on what to do if hypoNa-compatible symptoms appear. 368 
  369 
HYPONATREMIA IN THE PATIENT WITH TRAUMA AND POLYTRAUMA  370 
Prevalence and etiology 371 
Little is known about hypoNa in patients with polytrauma (PT). In several studies, hypoNa has been reported in up to 372 
15% of patients after trauma or PT (96, 97). After PT, the occurrence of hypoNa can be related to the event per se (fluid 373 
depletion, hemorrhage), to the immediate treatment at the site of trauma or Emergency Department (hypotonic intravenous 374 
fluids), or to a pre-existing comorbidity disease, especially in the elderly. 375 
Mortality 376 
HypoNa is associated with poor prognosis and increased mortality in patients with crush syndrome: in a retrospective 377 
study conducted in Chinese reference hospitals during the Wenchuan earthquake the presence of hypoNA was common, 378 
up to 50% of patients were affected and 15% of them died. However, here the hypoNa was mainly correlated with the 379 
development of acute kidney failure (96). 380 
Notes on clinical features and diagnosis 381 
Hip fracture is the commonest cause of traumatic death in Europe: immediate surgery has been associated with higher 382 
rates of independent living, lower mortality rates, improved patient outcomes by reducing pain scores, and lowering the 383 
risk of decubitus ulcers. The occurrence of hypoNa  ([Na]+ <135 mEq/L) in the course of the pre-surgical planning was 384 
the main medical pre-operative risk factor for surgery delay after 36 hours from trauma (98). 385 
Rather than considering hypoNa always as a consequence of PT, this electrolyte disorder could be the cause of trauma: 386 
even mild hypoNa in fact has been associated with unsteady gait, falls, impaired concentration, and risk of fractures, 387 
especially hip and femur fractures (6, 99). In an extensive series of elderly adults, fracture risk incidence was higher in 388 
patients with HypoNa, also after adjusting for osteoporosis. Patients with moderate-severe hypoNa ([Na]+ <130 mEq/L)  389 
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presented an 11-fold risk of fractures  (100), and fragility fractures increased incrementally with a categorical decrease in 390 
median serum sodium levels in multivariate logistic regression models (101).  391 
Notes on treatment 392 
Specific consensus about the treatment of hypoNa targeted to PT patients has not been developed, yet. In general, we 393 
suggest to follow currently available guidelines and recommendations for the management of hypoNa.  394 
HypoNa is common in PT patients without neurological involvement: however, larger studies are needed to investigate 395 
the relationship between trauma and serum sodium levels, and hypotonic intravenous fluids should be supplied carefully 396 
to patients with PT.  397 
HypoNa is not always recognized in patients with PT: we suggest to pay attention to sodium balance in such patients. 398 
Population studies with a large number of participants have to be performed. 399 
 400 
HYPONATREMIA IN THE OUTPATIENT SETTING  401 
Prevalence and etiology: 402 
The prevalence of hypoNa in this setting greatly depends on the age of the population considered (102-105). In a young 403 
and ethnically diverse population, the prevalence of hypoNa was 6.3% (105), but with aging the potential risk of 404 
developing hypoNa increases (103, 106). 405 
In the outpatient setting, hyponatremic individuals are more likely to be smokers, to have black ethnicity, a history of 406 
diabetes mellitus, congestive HF or cirrhosis and to use thiazide diuretics, antiepileptic drugs or SSRI (103, 105). 407 
However, in the Dallas Heart Study, among hyponatremic individuals with no predisposing medical conditions, 20% of 408 
them had criteria discriminators of the diagnosis of SIAD (105). 409 
Mortality: 410 
There are limited data in the literature regarding hypoNa in the outpatient setting, but similarly to hospitalized patients, 411 
also in the outpatient studies hypoNa has been reported to be an independent mortality risk factor (9, 102, 105, 107, 108). 412 
In a recent survey, hypoNa was found to be associated with a nearly two-fold increase in deaths, even after adjusting for 413 
major risk factors (105). 414 
Specific notes on clinical features and diagnosis: 415 
HypoNa in the outpatient is more likely to be mild, chronic and asymptomatic (103, 105, 107). 416 
Actually, in clinical practice, hypoNa very often represents an incidental finding during an outpatient visit for another 417 
reason and it is difficult for the physician to formulate promptly a correct etiological diagnosis, which greatly depends on 418 
additional laboratory tests that may not be readily available. 419 
Notes on treatment: 420 
In the case of moderately or severely symptomatic hypoNa, hospitalization should be considered.  421 
In the case of hypoNa secondary to SIAD, when vaptans use is indicated, patients should be hospitalized, because of the 422 
need of close initial monitoring, and to identify the appropriate dose (9, 109). A day-hospital admission may be suitable 423 
if there are no other serious concomitant disorders (110). 424 
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A regular outpatient follow-up is recommended, to evaluate the effectiveness of the therapy as well as the possibility of 425 
discontinuing it.  426 
We suggest that hypoNa in this setting should be taken into consideration even if mild to moderate hypoNa to timely 427 
correct it, particularly in the elderly and in patients assuming drugs,  thus likely limiting the consequences of persistent 428 
low sodium levels. 429 
  430 
LIFE-THREATENING HYPONATREMIA                     431 
Prevalence and etiology: 432 
Acute and severely symptomatic hypoNa is rare. However, if not rapidly recognized and correctly treated, it may carry a 433 
high morbidity and mortality rate, even in previously healthy subjects, such as for example marathon runners, in which 434 
an incidence of 13% has been documented (111). Other causes can be represented by the rapid ingestion of large amounts 435 
of water, for example in psychiatric patients, or of other hypotonic liquids, such as in beer potomania or tea and toast diet. 436 
Other conditions associated with acute and potentially life-threatening hypoNa are the postoperative period, in particular 437 
after prostate transuretral resection or post uterine endoscopic surgery due to the use of hypotonic irrigant solutions, 438 
colonoscopy preparation, the use of some drugs such as oxytocin or cyclophosphamide, or a recent prescription of 439 
thiazides or desmopressin, and use of recreational drugs such as ecstasy (MDMA) (13, 112). The severity of the picture 440 
correlates both with the magnitude and the rate of sodium decrease. 441 
 442 
Mortality: 443 
Mortality in this setting has been noted to be as high as 55% (113). However, the estimate from a broad-based literature 444 
survey gives much lower values (114). 445 
Specific notes on clinical features and diagnosis: 446 
HypoNa may be itself the direct cause of death because of brain stem herniation due to cerebral edema for serum hypo-447 
tonicity. Risk factors for brain edema are both the rate and the depth of sodium fall.  448 
The risk of death as a consequence of brain edema is increased in the presence of an intracranial disease, in the case of 449 
post-operative hypoNa or acute water intoxication.   450 
Notes on treatment: 451 
Prompt infusion of hypertonic saline, independent of volume status, may save lives in life-threatening hypoNa.  452 
In this emergency setting hypertonic 3% NaCl saline solution is administered as a 100/150 mL bolus (or 2 ml/Kg of body 453 
weight) given over 10-20 min, strictly monitoring sodium levels (every 20 min), and repeating the bolus administration, 454 
as needed, up to a maximum of 3 times. According to the European guidelines, this protocol is recommended until a 455 
serum sodium increase of 5 mEq/L is achieved  (13). 456 
In the case of symptoms improvement and/or after a 5-6 mEq/L increase in serum sodium (symptoms relief can take 457 
longer), 3% NaCl should be stopped, but the i.v. access kept. Meanwhile a diagnosis-specific process should be initiated, 458 
and appropriate management performed (13, 14). 459 
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In the absence of symptoms improvement after the first few hours, i.v. hypertonic 3% NaCl saline should be continued 460 
aiming for an additional 1 mEq/L/h increase in serum sodium, limiting the overall 24 hours increase to 8-10 mEq/L and 461 
stopping anyway the infusion upon reaching a serum sodium level of 130 mEq/L (13, 14). Therapy should be guided by 462 
frequent monitoring of serum sodium concentration (possibly every 2 hours, but at least every 4 hours).  463 
 464 
HYPONATREMIA OVERCORRECTION: CONDITIONS AT RISK, PREVENTION, TREATMENT  465 
Excessive correction of hypoNa (i.e. too much and/or too rapid increase of serum sodium levels) is associated with an 466 
increased risk of negative neurologic outcomes (i.e. the ODS), especially in the chronic forms of hypoNa. On this regard, 467 
specific attention is to be paid to the fact that during sodium correction an adequate renal response to hypotonicity (i.e. 468 
an hypotonic polyuria) is often spontaneously (and rapidly) restored, even since the first 8-12 hours from treatment start. 469 
This usually happens when pathogenetic factors responsible for the electrolyte derangement are promptly taken away, 470 
such as for example by volume expansion with 0.9% saline in hypovolemic hypoNa, or by ceasing the trigger mechanism 471 
for inappropriate secretion/response to ADH (i.e. drugs or inflammation). Thus, since the most frequent cause of hypoNa 472 
overcorrection is actually the reactivation of the normal renal physiological response (increased free water clearance), 473 
special attention should be paid to hypoNa settings characterized by rapidly reversible causes (Table 1) (18). A hypotonic 474 
polyuria with maximally diluted urine output may in fact further increase the programmed/estimated rate of correction.  475 
In such a circumstance, administration of a hypotonic solution should be started, as intravenous 5% dextrose or free water 476 
by a nasogastric tube, initially at 10 ml/Kg/h over 1 h (13) or in repeated 3ml/kg infusions (14) and then matched to 477 
urinary output in terms of rate and tonicity; desmopressin (i.v. or s.c.) at 2-4 μg every 8 hours can be associated, in order 478 
to bring back the rate of correction to below 12 mEq/L/24 hours (or better to a target of 6-8 mEq/L in the first 24 hours) 479 
(13). It is mandatory that specific measures to blunt overcorrection of hypoNa must be implemented by/or under the 480 
direction of experienced medical personnel (13) . 481 
Another possible (and underrated) cause of overcorrection of hypoNa is represented by the administration of potassium 482 
salts along with NaCl, aiming at correcting coexisting hypokalemia/potassium depletion.  Based on the original Edelman 483 
equation, potassium and sodium salts are equivalent in terms of tonicity effects (115). In fact, in case of cellular potassium 484 
depletion, the administered potassium enters the cells, with ensuing Na exit in order to maintain the electrical equilibrium.  485 
Thus, serum sodium values increase (116). 486 
The risk of overcorrection is not significantly reduced by the use of specific formulas aimed at estimating the rate and the 487 
temporal trajectory of serum sodium during correction (117). Formulas may be useful to set the start of therapy, but they 488 
do not completely avoid the risk of overcorrection due to their inherent limitations: they do not take into account the 489 
possibility of a rapidly restored diluting capacity by the kidney, ongoing losses and other electrolyte supplements are 490 
difficult to be integrated in the calculation, as it is the case of potassium administration in potassium depletion (117). 491 
More conservatively, in these cases it is better to frequently check (at least every 4 hours in the first 24 hours) the actual 492 
serum sodium levels. 493 
Finally, it should kept in mind that some conditions are associated with a higher risk of ODS due to overly rapid correction 494 
of hypoNa: serum sodium levels less than 105 mEq/L, alcoholism, malnutrition, advanced liver disease (14) Table 1. 495 
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These conditions must be recognized even before the start of treatment and a great caution should be used in these 496 
situations. 497 
 498 
CONCLUSIONS 499 
Despite being the most common electrolyte disorder encountered in clinical practice, hypoNa is frequently 500 
underdiagnosed and/or not appropriately treated. This may be due to a lack of awareness of the implications of this 501 
condition on patient outcomes, particularly when hospital-acquired and mildly or moderately symptomatic. Appropriate 502 
workup and treatment in the various clinical settings associated with hypoNa require a multidisciplinary approach. In 503 
such a need, this task force has provided the above-outlined suggestions and warnings. Ineffective management of hypoNa 504 
can negatively affect patient prognosis. New therapeutic options for the correction of hypoNa, particularly vaptans, the 505 
vasopressin receptor antagonists, represent an effective tool to safely treat this disorder and improve outcomes among a 506 
wide range of patients with hypoNa secondary to SIAD. However, the different clinical scenarios in which hypoNa may 507 
occur suggest that a thoughtful and personalized management should be individuated. This scenario is even more complex 508 
when we consider that not all the hospitals are properly equipped to perform an accurate differential diagnosis of hypoNa. 509 
As an example, the infrequent availability of osmometers in the medium/small hospital facilities is a limiting factor for 510 
the diagnosis of SIAD. Thus, we propose that clinicians may refer to calculated serum and/or urinary osmolality according 511 
to recently reviewed formulae (118). 512 
A rapid recognition and optimal treatment of hypoNa can reduce the risk of death (119), also reducing the length of 513 
hospitalization and associated costs, and improving the quality of life.  514 
 515 
 516 
 517 
 518 
 519 
 520 
 521 
522 
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Table 1: Conditions at risk for hypoNa overcorrection 863 
 864 
CONDITION MECHANISM OF HYPERCORRECTION 
Hypovolemia Elimination of the stimulus for ADH secretion due to baroceptor activation 
by volume expansion by cristalloid  
Low solute diet (Beer potomay, tea 
and toast diet etc.)  
Diet correction increases dietary solute load  increased renal free water 
clearance 
Thiazide diuretic therapy Discontinuation of the drug directly restores renal diluting capacity 
SSRI antidepressive drug therapy  Discontinuation of the drug reduces the serotoninergic stimulus on ADH 
secretion 
Hypopituitarism Restoration of physiologic suppression of ADH secretion by cortisol 
replacement therapy  
Hypoxemia Elimination of non osmotic stimulus on ADH by normalization of blood 
gases  
Stress, pain, nausea Elimination of transient stimuli on ADH secretion 
Hypokalemia, potassium depletion With K administration, sodium leaves the cell in exchange with potassium 
entrance, in order to maintain electroneutrality 
 865 
 866 
 867 
 868 
 869 
 870 
 871 
 872 
 873 
 874 
 875 
 876 
 877 
 878 
 879 
 880 
 881 
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Table 2  Diagnosis of SIAD [modified from (120)] 883 
 884 
 885 
Essential features 886 
 887 
Decreased effective osmolality (< 275 mOsm/Kg of water) 888 
Urine osmolality > 100 mOsm/Kg of water 889 
Clinical euvolemia 890 
- No clinical signs of volume depletion of extracellular fluid (orthostasis, tachycardia, decreased skin turgor, or 891 
dry mucous membranes) 892 
- No clinical signs of excessive volume of extracellular fluid (edema or ascites) 893 
Urinary sodium > 40 mmol/liter with normal dietary salt intake 894 
Normal thyroid and adrenal function 895 
No recent use of diuretic agents 896 
 897 
Supplemental features 898 
 899 
Plasma acid uric < 4 mg/dL 900 
Blood urea nitrogen < 10 ml/dL 901 
Fractional sodium excretion > 1%; fractional urea excretion > 55% 902 
Failure to correct hyponatremia after 0.9% saline infusion 903 
Correction of hyponatremia through fluid restriction 904 
Abnormal results on test of water load (< 80% excretion of 20 ml of water per kilogram of body weight over a period of 905 
4 hours), or inadeguate urinary dilution (< 100 mOsm/Kg of water) 906 
Elevated plasma AVP levels, despite the presence of hypotonicity and clinical euvolemia 907 
 908 
 909 
  910 
 911 
 912 
 913 
 914 
 915 
 916 
 917 
 918 
 919 
 920 
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 923 
Table 3 Drugs possibly used in oncological patients that may induce hyponatremia 924 
DRUGS  INDICATION  
 
for use 
MECHANISM 
INVOLVED 
REFERE
NCES 
 
 Vinca alkaloids vincristine, vinblastine 
 Platinum compounds  
cisplatin, carboplatin 
 Alkylating agents  
ev cyclophosphamide, melphalan, ifosfamide 
 Antracyclines     
 TK and monoclonal antibody inhibitor 
Afatinib 
Brivanib 
Cetuximab  
Gefinib 
Limifanib  
Pazopanib 
Sorafenib  
Vorinostat 
 Others 
Metothexate 
IFN α-γ 
Pentostatina 
IL2 
 
Chemotherapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increase AVP secretion 
Increase AVP secretion 
and renal waist syndrome 
Increase AVP secretion 
and  
increase renal sensitivity 
Ipervolemic hyponatremia  
 
Direct natriuretic effect 
and interference in Na 
pathway and 
increase AVP secretion 
Possible role for 
iatrogenic hypotiroidism 
 
 
 
 
Increase AVP secretion 
and  
possible fluid 
redistribution 
 
(23), 
(121),(122) 
(123) 
 
 
 
 
(122, 123) 
 
(121, 122) 
(124) 
 
 
(122, 125)   
 
 
 
 
 
(23, 121-
123) 
  
 
 Opioid  
 Acetaminophen 
 Non-steroidal anti-inflammatory drugs  
 
Pain control 
 
 
 
Increased renal sensitivity, 
indirect increase in ACP 
secretion secondary to 
nausea or hypotension 
 
(23, 122, 
123) 
 
 Triciclyc antidepressant 
Amitryptiline 
Protryptiline 
Antidepressant Increase AVP secretion 
 
 
(23, 122, 
123) 
 
26 
 
 26 
Desipramine 
 SSRI 
 MAO inhibitors 
 Others  
Duloxetine, Venlafaxine, Mitrazapina  
 
 
 
 
 
Reset osmostat 
 
 
 
 
 
(23) 
 Carbamazepine,Oxcarbazepine 
 Sodium valproato 
 Lamotrigine 
Antiepilectic Increase AVP secretion 
and potentiation AVP 
effect  
Reset osmostat 
 
 
(23, 123, 
126) 
 
 Phenotiazine Antiemetic Drug induced polydipsia (122) 
 Corticosteroid  Anti-edema, 
nausea  
Hyperglycemia – 
pseudohyponatremia 
(122, 123) 
 First antidiabetic generation 
Clorpropamide, Tolbutamide 
Diabete Potentiation AVP effect (123) 
 Antibiotics 
Ciprofloxacina 
Trimethoprim/sulphametoxazole 
Linezolid 
Cefoperazone sulbactam 
  
Infections 
 
 
Increase AVP secretion 
 
Hypovolemic 
hyponatremia 
(23) 
 
(127) (128)  
 
 Proton pump inhibitor  
Omeprazole, esomeprazolo 
Prevention gastric 
ulceration stress 
or or drug related    
Increase AVP secretion (23) 
 Hypotensive drug 
Diuretic loop 
furosemide 
ACE-I 
thiazide 
 
Hypertension 
therapy 
 
Hypovolemic 
hyponatremia 
Increase osmotic renal 
losses  
Increase AVP secretion 
Increase of thirst 
 
(23) 
 Mannitol Anti –edema  Pseudohyponatremia  
 
(122, 123) 
 Hypotonic solution 
 Isotonic solution 
Hydratation 
 
Diluitional (122, 123) 
  925 
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Table 4: Causes of HypoNa in cancer patients [modified from Ref. (22)]. 927 
CAUSES % 
SIAD 30.4 
Dehydration 28.7 
Diuretic use 14.0 
Hypervolemia 7.8 
Kidney failure 3.5 
Hypotonic solutions 1.7 
Miscellaneous 5.2 
Not defined 1.7 
False positive 7.0 
Mixed causes 9.6 
Total 100 
 928 
 929 
 930 
 931 
 932 
 933 
 934 
 935 
 936 
 937 
 938 
 939 
 940 
 941 
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Table 5: Drugs commonly used in elderly patients that may cause or worsen hypoNa  (129) (130) (131) (132) (133)  942 
 943 
DRUG CLASSES Principal drugs involved in the 
class 
 Diuretic drugs 
 
loop diuretics 
thiazides 
 Second-generation 
antidepressants 
citalopram, escitalopram, 
paroxetine, fluoxetine, 
fluvoxamine, venlafaxine, 
duloxetine, mirtazapine, or 
sertraline 
 Proton pump inhibitors omeprazole, esomeprazole 
 Hypotensive drugs Angiotensin-converting enzyme 
inhibitor 
 944 
